HHS unveiled a plan aimed at speeding early-stage clinical trials by 6 to 12 months, targeting the development bottleneck from IND to first patient dosing. The initiative is described as part of a broader effort to modernize and expedite clinical research in the US, with officials explicitly framing the move around regaining ground versus China’s early-stage trial growth. According to the announcement, the pilot program will align with FDA-focused pathways and is tied to the 2027 fiscal budget request for Congress to create a more permanent faster process for the existing IND pathway. The plan also builds on calls championed by former FDA Commissioner Marty Makary, even as officials said the work was already underway. The changes could affect protocol design cycles, site activation timelines, and operational readiness requirements for sponsors seeking faster go/no-go decisions in first-in-human studies. For biotech, the risk is reduced time-to-data without reduced scrutiny; for the regulator, the goal is more efficient trial initiation while sustaining safety review standards.